Clinical value of the early use of ulinastatin in patients with moderately severe or severe acute pancreatitis

National Medical Journal of China

Volumn 97, Issue 16, 2017, Pages 1252-1255

  Wang, Jun ^a   Jin, Jun ^a   Huang, Jian ^a   Li, Dongrong ^a   Hao, Yan ^a   Kong, Jindan ^a   Chu, Zhenyu ^a   Fu, Jianhong ^a   Huang, Fang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Acute kidney injury; Acute respiratory distress syndrome; Pancreatitis; Shock; Ulinastatin

Indexed keywords

AMYLASE; C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; SOMATOSTATIN; TUMOR NECROSIS FACTOR; ULINASTATIN; GLYCOPROTEIN; INTERLEUKIN DERIVATIVE; TRYPSIN INHIBITOR;

ABDOMINAL PAIN; ABDOMINAL PRESSURE; ACUTE PANCREATITIS; AMYLASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEFECATION; DISEASE SEVERITY; DISEASE SEVERITY ASSESSMENT; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG USE; EARLY INTERVENTION; HUMAN; INCIDENCE; INFLAMMATION; INTENSIVE CARE UNIT; LENGTH OF STAY; LEUKOCYTE COUNT; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; UNIVERSITY HOSPITAL; ACUTE DISEASE; METABOLISM; PANCREATITIS;

ACUTE DISEASE; DOWN-REGULATION; GLYCOPROTEINS; HUMANS; INTERLEUKIN-6; INTERLEUKINS; PANCREATITIS; PROSPECTIVE STUDIES; TRYPSIN INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85020123692     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2017.16.015     Document Type: Article

References (9)

1. Papa C. Prognostic biological facters in severe acute pancreatitis [J]. Med life, 2014, 7(4): 525-528
2. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute paiicreatitis-2012; revision ol the Atlanta classification and definitions by international consensus [J]. Gut, 2013, 62 (1): 102-111. DOI: 10.1136/gutjnl-2012-302779.
3. AMDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome; the Berlin Definition [J]. JAMA, 2012, 307 (23); 2526-2533. DOI: 10.1001/jama. 2012.5669.
4. Khwaja A. KD1G0 clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4) :cl79-184. DOI; 10.1159/000339789.
5. Rotstein OD. Circulating cytokines in predicting development ol severe acute pancreatitis [J]. Crit Care, 2014, 18(5); 575. DOI: 10.1186A13054-014-0575-0.
6. De Waele JJ. Acute pancreatitis[J]. Curr Opin Crit Care, 2014, 20(2): 189-195. DOI: 10.1097/MCC.0000000000000068.
7. Chooklin S. Pathogenic aspects of pulmonarycomplications in acute pancreatitis patients [J]. Hepatobiliary Pancreat Dis Ini, 2009, 8(2); 186-192.
8. Zhang J, Niu J, Yang J. Interleukin-6, interleukin-8 and interleukin-10 in estimating the severity of acute pancreatitis; an updated meta-analysis [J]. Hepatogastroenterology, 2014, 61 (129); 215-220.
9. Sternby II, Hartman H, Johansen D, et al. Predictive Capacity of Biomarkers for Severe Acute Pancreatitis [J]. Eur Surg Res, 2016, 56(34); 154-163. DOI: 10.1159/000444141.